Crinetics presents six abstracts at ENDO 2026, including two-year paltusotine OLE data and full Phase 2 atumelnant results in CAH. The data set tests both commercial durability and pipeline optionality.
Alpha Score of 58 reflects moderate overall profile with moderate momentum, moderate value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Crinetics Pharmaceuticals (CRNX) will present six abstracts at the Endocrine Society's ENDO 2026 meeting in Chicago from June 13-16. The data set includes two oral presentations on the approved acromegaly drug PALSONIFY (paltusotine) and two on the investigational ACTH receptor antagonist atumelnant. For traders, the conference represents the first major clinical data readout since paltusotine received U.S. and E.U. approvals, shifting the focus from regulatory clearance to real-world differentiation and pipeline depth.
The six abstracts break into two clear categories: durability data for the approved drug and proof-of-concept expansion for the pipeline candidate.
Three abstracts address paltusotine in acromegaly. The headline oral presentation covers up to two years of efficacy and pooled safety data from the PATHFNDR-1 and PATHFNDR-2 open-label extension (OLE) studies. This is the first look at sustained biochemical control beyond the pivotal trial period.
A second poster evaluates real-world biochemical control using U.S. claims and laboratory data. This abstract directly addresses the commercial question: how many acromegaly patients remain suboptimally controlled on current therapies, and where does paltusotine fit in the treatment sequence?
A third poster assesses long-term safety and efficacy of paltusotine in combination with cabergoline from the ACROBAT Advance trial. This matters because combination therapy is common in clinical practice for patients who do not achieve full control on monotherapy.
Three abstracts cover atumelnant, Crinetics' investigational ACTH receptor antagonist. One oral presentation reports full Phase 2 data in congenital adrenal hyperplasia (CAH). A second oral presents new interim results from a Phase 1b/2a study in ACTH-dependent Cushing's syndrome. A rapid-fire presentation covers dose selection data for the planned Phase 3 trial in CAH.
These presentations are the first comprehensive public data for atumelnant in both indications. The CAH data are particularly important because current treatment options are limited and often require supraphysiologic glucocorticoid doses with significant side effects.
Crinetics has two distinct value drivers at this conference, and each creates a different trading question.
The paltusotine story has shifted from binary regulatory risk to commercial execution. The OLE data will be scrutinized for any signal of waning efficacy or unexpected long-term toxicity. The real-world claims analysis is a direct input into peak sales estimates. If the data show a large untreated or undertreated population, the addressable market expands.
Key insight: The real-world claims abstract is more commercially relevant than the OLE data. It tells investors whether the drug is entering a growing or shrinking market.
Atumelnant represents the next catalyst for the stock, independent of paltusotine sales. Full Phase 2 data in CAH will inform whether the drug can differentiate from existing therapies on efficacy, safety, or dosing convenience. The Cushing's syndrome data, while interim, will show whether the mechanism works across multiple ACTH-driven conditions.
Risk to watch: Atumelnant is an oral ACTH receptor antagonist, a novel mechanism. The Phase 2 data must show a clean safety profile, particularly regarding adrenal insufficiency and electrolyte disturbances, which are known risks for this class.
Crinetics has a market capitalization that reflects paltusotine's approved status plus optionality for atumelnant. The stock trades at a premium to pure commercial-stage biotech peers because of the pipeline. The ENDO data will either validate or challenge that premium.
| Asset | Stage | Key Data at ENDO | Commercial Impact |
|---|---|---|---|
| PALSONIFY (paltusotine) | Approved (U.S. & E.U.) | 2-year OLE, real-world claims, cabergoline combo | Peak sales estimates, market share trajectory |
| Atumelnant (CAH) | Phase 2 complete | Full Phase 2 results | Phase 3 design, regulatory path |
| Atumelnant (Cushing's) | Phase 1b/2a | Interim results | Proof-of-concept expansion |
Bull case confirmation:
Bear case triggers:
ENDO 2026 creates a binary event for the atumelnant pipeline and a confirmation event for paltusotine's commercial thesis. The stock's reaction will depend on whether the data confirm the bull case or introduce new risks.
For traders holding CRNX into the conference, the key variable is the atumelnant CAH data. Paltusotine data are unlikely to surprise negatively given the approved label and existing clinical data. Atumelnant, however, has no prior full Phase 2 readout in CAH. The data will set expectations for the Phase 3 program and, by extension, the stock's pipeline premium.
For those not positioned, the conference provides a clean entry point if the data are strong. The product theater on June 15, featuring a patient living with acromegaly, adds a qualitative dimension that may influence sentiment but is not directly tradeable.
Crinetics' Alpha Score is 70/100 (Moderate), reflecting the approved product revenue stream balanced against pipeline execution risk. The stock page is at /stocks/crnx.
The ENDO 2026 data set gives investors two independent catalysts in one conference. Paltusotine durability data support the commercial thesis. Atumelnant Phase 2 data define the next pipeline milestone. The market will price both simultaneously, creating a wider-than-usual range of potential outcomes. Position sizing should reflect that the atumelnant data carry higher uncertainty than the paltusotine data.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.